CRI report: Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. Globally, the disease affects up to 10% of women. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding and infertility. Endometriosis has the potential to disrupt the quality of life of women, leading to emotional distress, loss of work productivity, physical limitations, and social withdrawal. In addition to the impact on psychological, physical and social well-being, hospitalization and high medication costs also cause a substantial economic burden for women with endometriosis (Abbott, 2013; ASRM, 2012; Bulletti et al., 2010; Fourquet et al., 2011; Nnoaham et al., 2011; Nucci and Oliva, 2009; Simoens et al., 2012; Velebil et al., 1995; Xin et al., 2006).
To forecast the diagnosed prevalent cases of endometriosis in the 6MM (US, France, Germany, Italy, Spain, and UK), EpiCast Report: Endometriosis - Epidemiology Forecast to 2022 used nationally representative studies published in peer-reviewed journals that provided diagnosed prevalence of endometriosis. GlobalData epidemiologists also used consistent forecast methodology across all the 6MM to allow for a meaningful comparison of the diagnosed prevalent cases of endometriosis in the 6MM, which is the major strength of the forecast. In addition, GlobalData epidemiologists provided diagnosed prevalent cases of endometriosis in the 6MM segmented by stage based on the American Society of Reproductive Medicine (ASRM) guidelines.
EpiCast Report: Endometriosis - Epidemiology Forecast to 2022 forecast an increase in the diagnosed prevalent cases of endometriosis in the 6MM, from 5.66 million prevalent cases in 2012 to 5.86 million prevalent case in 2022, at a growth rate of 3.4% over the forecast period. The US constituted the largest proportion (almost 90%) of the prevalent cases of endometriosis, with 5.24 million prevalent cases in 2022. Endometriosis is not a life-threatening condition and is largely influenced by hereditary factors. However, the condition will cause substantial economic, physical and psycho-social burden to the individual, as well as to the healthcare system, during the forecast period.